Director & 10% Owner Buys $128K in Open Market Amidst Financial Concerns
GDTC sits 68% above its 52-week low of $0.68 on light trading volume (0.2× avg).
Summary
A Director and 10% owner of CytoMed Therapeutics purchased $128,778 in open market shares, signaling confidence despite recent financial distress.
Key Events · Ownership and Investor Activity · GDTC
-
Director & 10% Owner Buys Shares
Choo Chee Kong, a Director and 10% owner, purchased 112,000 shares of CytoMed Therapeutics in the open market for a total of $128,778 at $1.15 per share on May 13, 2026.
-
Insider Confidence Amidst Financial Distress
This significant insider purchase provides a positive signal of confidence, coming after the company disclosed a going concern warning and widened net losses in recent filings.
-
Substantial Investment
The $128,778 investment is notable for a company of this market capitalization, representing nearly 1% of the company's total value.
Analysis · GDTC · Life Sciences
This open market purchase by a Director and 10% owner is a strong signal of insider confidence, especially significant given the company's recent financial challenges, including a going concern warning and widened net losses. The investment of $128,778 represents a substantial commitment relative to the company's market valuation.
At the time of this filing, GDTC was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.